What is Leucid Bio?
Leucid Bio operates at the intersection of synthetic biology and clinical oncology. The company is dedicated to the development of novel cell therapies designed to overcome the immunosuppressive barriers often found in solid tumors. By utilizing its proprietary CAR T platform, Leucid Bio is building a robust pipeline of candidates that aim to provide durable responses for patients who have exhausted standard-of-care options. Their market position is defined by a commitment to rigorous scientific validation and the translation of complex biological insights into scalable therapeutic products.
How much funding has Leucid Bio raised?
Leucid Bio has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2021): $16M with participation from Epidarex Capital, Vulpes Investment Management, Future Fund, and 2Invest
Key Investors in Leucid Bio
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, utilizing deep scientific networks to create exceptional value.
Vulpes Investment Management
Vulpes Investment is an opportunistic alternative investment manager that prioritizes long-term value creation and aligns incentives through a patient, family-office-style investment approach.
Future Fund
Future Fund is an Australian sovereign wealth fund established to invest for the benefit of future generations, providing long-term financial stability and support for public sector liabilities.
What's next for Leucid Bio?
With the infusion of this latest capital, Leucid Bio is expected to accelerate its transition from preclinical research into advanced clinical development phases. The strategic roadmap likely includes the expansion of its internal research capabilities and the initiation of human trials for its lead candidates. As the company scales, the focus will remain on optimizing its CAR T manufacturing processes and establishing key partnerships to navigate the regulatory landscape. The backing from specialized life science investors provides the necessary runway to achieve critical milestones in the competitive landscape of oncology therapeutics, potentially setting a new standard for solid tumor treatment efficacy.
See full Leucid Bio company page
